Abstract 200P
Background
Understanding the complex biology of metastatic tumors is critical for advancing cancer biology research and improving therapeutic interventions. To address this challenge, we have developed a novel multi-organ-on-chip (Multi-OOC) platform designed to unravel the intricacies of breast to bone (B2B) metastatic tumor growth. This innovative platform integrates organ-specific tissue models fluidically interconnected to mimic the dynamic interactions between primary tumor and distant organ during metastasis. By replicating the physiological microenvironments of various target organs, our model provides a unique opportunity to investigate the entire metastatic cascade, from tumor cell dissemination, circulating tumor cells (CTCs) survival under flow and colonization. In order to support real-time monitoring of cellular infiltration and response to therapeutic agents in a multi-organ context optically transparent OOC device has been developed, compatible with the optical microscope observation.
Methods
A breast cancer cell laden hydrogel has been developed by using MDA-MB-231 cells with and without endothelial cells (HUVEC), forming the capillary network. A computational fluid dynamic simulation was done to set up the proper capillary velocity and induced shear stresses. In a second chamber, a bone tissue model was developed as metastasis target: different ratio of hydroxyapatite (HA) has been included in a polymeric matrix to introduce a bone like mineral phase. Tumor cell infiltration and CTC survival rate have been monitored using different fluid-dynamic conditions and HA content.
Results
A multicompartmental OOC has been developed and successfully validated. The 3D breast cancer model displayed long term (2 months) survival in vitro in dynamic conditions, and a cells cytoskeleton reorganization was highlighted. The CTCs survival was shown correlated to the shear stresses induced by the fluid flow into the Multi-OOC. Different levels of CTCs infiltration in the mineralized matrix hosted in the metastatic OOC chamber were observed.
Conclusions
This platform holds great promise for accelerating the development of targeted therapies and personalized treatment strategies, ultimately advancing our understanding of metastatic cancer biology.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Aiello, S. Scaglione: Financial Interests, Personal, Member of Board of Directors: React4life. All other authors have declared no conflicts of interest.
Resources from the same session
156TiP - The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Elin Marie Stensland
Session: Poster Display
157TiP - Krascendo-170 Lung: a phase Ib/II study of divarasib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ferdinandos Skoulidis
Session: Poster Display
159TiP - Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]) or Ipilimumab (INCB 99280-205 [Study 205]) in Adults with Advanced Solid Tumors
Presenter: David Berz
Session: Poster Display
160TiP - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress
Presenter: Ignacio Melero
Session: Poster Display
164P - Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1/NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma
Presenter: Anlin Li
Session: Poster Display
165P - Immunosuppressive F13A1+ Mo/M_ in the tumor microenvironment as a hallmark for multiple primary lung cancers
Presenter: Jiahao Qu
Session: Poster Display
166P - Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model
Presenter: Yan Zhou
Session: Poster Display
167P - Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.
Presenter: Triparna Sen
Session: Poster Display
168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC
Presenter: CATERINA DE ROSA
Session: Poster Display